Oppenheimer & Co. Inc. Sells 4,050 Shares of Core Laboratories Inc. (NYSE:CLB)

Oppenheimer & Co. Inc. lowered its position in shares of Core Laboratories Inc. (NYSE:CLB) by 28.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,087 shares of the oil and gas company’s stock after selling 4,050 shares during the period. Oppenheimer & Co. Inc.’s holdings in Core Laboratories were worth $187,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Sei Investments Co. boosted its holdings in Core Laboratories by 91.8% in the first quarter. Sei Investments Co. now owns 36,303 shares of the oil and gas company’s stock worth $620,000 after purchasing an additional 17,371 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Core Laboratories by 0.5% in the first quarter. Vanguard Group Inc. now owns 5,392,034 shares of the oil and gas company’s stock worth $92,096,000 after purchasing an additional 27,701 shares during the last quarter. PEAK6 Investments LLC boosted its holdings in Core Laboratories by 106.5% in the first quarter. PEAK6 Investments LLC now owns 61,005 shares of the oil and gas company’s stock worth $1,042,000 after purchasing an additional 31,459 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Core Laboratories by 8.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 27,450 shares of the oil and gas company’s stock worth $469,000 after purchasing an additional 2,070 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in Core Laboratories by 23.9% in the second quarter. GAMMA Investing LLC now owns 4,425 shares of the oil and gas company’s stock worth $90,000 after purchasing an additional 855 shares during the last quarter. Institutional investors own 97.81% of the company’s stock.

Core Laboratories Trading Up 0.8 %

Shares of Core Laboratories stock opened at $21.28 on Friday. The company’s fifty day simple moving average is $19.27 and its 200-day simple moving average is $19.44. The stock has a market capitalization of $999.10 million, a PE ratio of 32.74, a P/E/G ratio of 1.42 and a beta of 2.35. Core Laboratories Inc. has a 1-year low of $13.82 and a 1-year high of $25.13. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.48 and a quick ratio of 1.79.

Core Laboratories (NYSE:CLB) last issued its quarterly earnings results on Wednesday, October 23rd. The oil and gas company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.04. The business had revenue of $134.40 million for the quarter, compared to analysts’ expectations of $134.16 million. Core Laboratories had a net margin of 5.83% and a return on equity of 15.84%. The company’s revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.22 EPS. As a group, equities analysts anticipate that Core Laboratories Inc. will post 0.8 earnings per share for the current year.

Core Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 25th. Investors of record on Monday, November 4th will be paid a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.19%. The ex-dividend date is Monday, November 4th. Core Laboratories’s dividend payout ratio (DPR) is 6.15%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on CLB shares. Citigroup dropped their target price on shares of Core Laboratories from $15.00 to $14.00 and set a “sell” rating on the stock in a report on Thursday, October 31st. StockNews.com upgraded shares of Core Laboratories from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. Two equities research analysts have rated the stock with a sell rating and three have assigned a hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $17.00.

Core Laboratories Company Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.